grant

Molecular subtyping of brain tumors using a blood-based multiplexed assay

Organization MASSACHUSETTS GENERAL HOSPITALLocation BOSTON, UNITED STATESPosted 3 Apr 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY2026AbscissionAdherenceAlgorithmic AnalysesAlgorithmic AnalysisAnalyses of AlgorithmsAnalysis of AlgorithmsAnatomic SitesAnatomic structuresAnatomyAreaAssayAstrocytic GliomaAstrocytic NeoplasmAstrocytic TumorAstrocytomaAstrogliomaAwardAwarenessB-raf-1BRAFBRAF geneBioassayBiological AssayBiometricsBiometryBiopsyBiostatisticsBlindedBloodBlood PlasmaBlood Reticuloendothelial SystemBody TissuesBrain CancerBrain NeoplasiaBrain NeoplasmsBrain TumorsCNS TumorCNS neoplasmCancersCaringCentral Nervous System NeoplasmsCentral Nervous System TumorsCertificationCharacteristicsClassificationClinicalClinical Laboratory Improvement AmendmentsClinical TrialsCollaborationsComplexDNADNA mutationDecision MakingDeoxyribonucleic AcidDetectionDevelopmentDiagnosisDiagnosticDiseaseDisease stratificationDisorderEGF ReceptorEGFREGFRvIIIERBB ProteinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsExcisionExtirpationGCP standardGeneral HospitalsGenesGeneticGenetic ChangeGenetic defectGenetic mutationGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGoalsGoldGood Clinical PracticeGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHER1HGPRTHPRT1HPRT1 geneHistologicHistologicallyHistologyHistopathologyHumanImmune mediated therapyImmunologically Directed TherapyImmunotherapyInduction TherapyIndustryIndustry StandardInfiltrationIntentionInternationalInterventionLaboratoriesLesionLocationMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMapsMassachusettsMeasuresMedical DeviceMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMethodsModalityModern ManMolecularMolecular FingerprintingMolecular ProfilingMonitorMutationMutation DetectionNEOADJNMR ImagingNMR TomographyNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeuroglial NeoplasmNeuroglial TumorNeurosurgeonNon-Polyadenylated RNANuclear Magnetic Resonance ImagingOperative ProceduresOperative Surgical ProceduresPatient CarePatient Care DeliveryPatientsPerformancePhasePlasmaPlasma SerumPoint MutationProceduresProductivityPrognosisQuality ControlRAFB1RNARNA Gene ProductsRemovalReproducibilityResearchReticuloendothelial System, Serum, PlasmaRibonucleic AcidSamplingSensitivity and SpecificitySourceSpecificityStandardizationStratificationSurgeonSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalSystematicsTGF-alpha ReceptorTechnologyTestingTherapeuticTissuesTransforming Growth Factor alpha ReceptorTranslatingTumor TissueUrogastrone ReceptorValidationWorkZeugmatographyaccurate diagnosisalgorithm developmentbrain tissuec-erbB-1c-erbB-1 Proteincare for patientscare of patientscaring for patientscell free DNAcell free circulating DNAchemotherapyclinical applicabilityclinical applicationclinical careclinical decision-makingclinical implementationclinical significanceclinical validationclinically significantcohortcross reactivityddPCRdetection limitdevelopmentaldiagnosis standarddigitaldisease diagnosisdisease prognosisdisease prognosticationdroplet digital PCRdroplet digital Polymerase Chain Reactiondroplet-based digital PCRepidermal growth factor receptor VIIIerbB-1erbB-1 Proto-Oncogene ProteinerbBlexosomeexperimentexperimental researchexperimental studyexperimentsexpression subtypesextracellularextracellular vesiclesgenome mutationglial-derived tumorglioblastoma multiformehigh riskimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedin-vitro diagnosticsinduction therapiesindustrial partnershipindustry partnerindustry partnershipliquid biopsylow-frequency mutationmachine learned algorithmmachine learning algorithmmachine learning based algorithmmalignancyminimally invasivemolecular profilemolecular signaturemolecular sub-typesmolecular subsetsmolecular subtypesmulti-modalitymultimodalitymultiplex assaymutantmutational statusneoplasm/cancerneural imagingneuro-imagingneuro-surgeonneuroglia neoplasmneuroglia tumorneuroimagingneurological imagingnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyoligodendrogliomapatient populationpatient stratificationpost implementationproto-oncogene protein c-erbB-1quality assurancerapid assayrapid testrapid testsrare allelerare mutationrare variantresectionresponse to therapyresponse to treatmentsmall moleculespongioblastoma multiformestratified patientsuccesssurgerytherapeutic responsetherapy responsetooltreatment responsetreatment responsivenesstumortumor diagnosistumor of the central nervous systemtumors in the braintumors in the central nervous systemv-raf Murine Sarcoma Viral Oncogene Homolog B1validations
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

SUMMARY
Gliomas are typically characterized by high malignancy and poor prognosis. The most recent WHO

classification of CNS neoplasms has advanced the diagnostic framework to stratify disease by incorporating

tumor histological features and genetic/molecular mutations. The current standard of diagnosis and monitoring

is neuroimaging followed by…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Molecular subtyping of brain tumors using a blood-based multiplexed assay — MASSACHUSETTS GENERAL HOSPITAL | UNITED STAT | Dev Procure